Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers
- PMID: 24370903
- DOI: 10.1245/s10434-013-3429-0
Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers
Abstract
Background: Circulating factors in patients with gastric/gastroesophageal junction (GEJ) cancers may promote tumor progression and metastasis and may be targeted for therapy.
Methods: Serum levels of ligands-vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF2), epidermal growth factor (EGF), hepatocyte growth factor (HGF)-from four targetable pathways were measured before surgery, and levels were correlated to clinicopathologic characteristics and overall survival (OS).
Results: In 147 patients who underwent potentially curative resection for gastric/GEJ adenocarcinoma, VEGF-A levels were higher in patients with R1 versus R0 resection (p = 0.037). High EGF levels were associated with poorly differentiated tumors (p = 0.02). Elevated FGF2 levels were found in Lauren diffuse-type tumors (p = 0.017) and tumors with seven or more metastatic nodes (N3) (p < 0.042). Patients with advanced-staged tumors had higher HGF levels (p = 0.012). At a median follow-up of 35 months, 46 patients (31 %) had died. Increased VEGF and HGF levels were correlated with decreased OS (p = 0.009 and 0.005). An adjusted total value (ATV) of all factors was better than any single factor in stratifying patients into good and poor prognosis groups (5-year OS 84.1 vs. 53.9 %, p = 0.005). By multivariate analysis, serum VEGF-A and ATV were significant independent prognostic factors (along with T and N category) for OS (p = 0.028 and 0.013, respectively).
Conclusions: In patients undergoing resection for gastric and GEJ cancer, high levels of angiogenic and growth factors are associated with unfavorable tumor characteristics and poorer overall survival. Thus levels of these factors can help delineate tumor biology and stratify prognosis.
Similar articles
-
Extranodal metastasis is a powerful prognostic factor in patients with adenocarcinoma of the esophagogastric junction.J Surg Oncol. 2013 Dec;108(8):542-9. doi: 10.1002/jso.23430. Epub 2013 Sep 9. J Surg Oncol. 2013. PMID: 24018956
-
Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome.Ann Surg Oncol. 2007 Feb;14(2):306-16. doi: 10.1245/s10434-006-9166-x. Epub 2006 Nov 8. Ann Surg Oncol. 2007. PMID: 17091329
-
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.Dis Esophagus. 2013 Apr;26(3):299-304. doi: 10.1111/j.1442-2050.2012.01369.x. Epub 2012 Jun 7. Dis Esophagus. 2013. PMID: 22676551 Clinical Trial.
-
Comparison between site N-category and number N-category for nodal staging in carcinoma of the gastroesophageal junction: our experience and literature review.Am Surg. 2006 Feb;72(2):118-23. Am Surg. 2006. PMID: 16536239 Review.
-
Individualized surgical strategies for cancer of the esophagogastric junction.Ann Chir Gynaecol. 2000;89(3):191-8. Ann Chir Gynaecol. 2000. PMID: 11079787 Review.
Cited by
-
Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma.J Gastrointest Oncol. 2016 Dec;7(6):828-837. doi: 10.21037/jgo.2016.08.09. J Gastrointest Oncol. 2016. PMID: 28078107 Free PMC article.
-
Blood-based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer.J Cancer. 2020 Apr 27;11(15):4332-4342. doi: 10.7150/jca.44545. eCollection 2020. J Cancer. 2020. PMID: 32489452 Free PMC article. Review.
-
Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.Oncotarget. 2016 Jan 26;7(4):4925-38. doi: 10.18632/oncotarget.6753. Oncotarget. 2016. PMID: 26716644 Free PMC article.
-
Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal model.Oncotarget. 2014 Jul 15;5(13):5029-39. doi: 10.18632/oncotarget.2078. Oncotarget. 2014. PMID: 24970807 Free PMC article.
-
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.Target Oncol. 2024 Jan;19(1):59-69. doi: 10.1007/s11523-023-01027-8. Epub 2024 Jan 9. Target Oncol. 2024. PMID: 38194163 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials